GlassScriptPhysician profile
Michelle M Loeber
NPI 1184967887
$9,574.08
in general payments reported to CMS, 2019-2025
26 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,201 · 2022: $2,126 · 2023: $2,947 · 2024: $2,849 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,053 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,053.26 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,120.75 | 2021-2025 | |
| Janssen Biotech, INC. | $1,301.75 | 2021-2024 | Tremfya, Simponi Aria |
| Amgen INC. | $1,165.57 | 2022-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $760.91 | 2022-2024 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $594.32 | 2022-2024 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $586.23 | 2022-2024 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $525.52 | 2021-2025 | Orencia |
| Horizon Therapeutics Plc | $414.33 | 2021-2023 | Krystexxa |
| Pfizer INC. | $330.44 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $289.21 | 2022-2025 | |
| Lilly USA, LLC | $260.89 | 2022-2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.74 | 2021-2024 | Cyltezo, Ofev |
| Glaxosmithkline, LLC. | $188.14 | 2021-2024 | Benlysta |
| Merz North America, INC. | $158.09 | 2024 | |
| Genzyme Corporation | $119.30 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $99.44 | 2023-2024 | Idacio |
| Aurinia Pharma U.S., INC. | $85.74 | 2023-2024 | Lupkynis |
| Genentech USA, INC. | $84.77 | 2022-2023 | Actemra |
| Ani Pharmaceuticals, INC. | $73.64 | 2022-2023 | Purified Cortrophin Gel |
| Radius Health, INC. | $57.02 | 2022-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $43.11 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $33.17 | 2021 | |
| Fidia Pharma USA INC. | $22.86 | 2024 | Hymovis |
| Octapharma USA, INC. | $20.66 | 2023 | Octagam Immune Globulin (Human) |
| Sandoz INC. | $18.70 | 2023 | Hyrimoz |
| Teva Pharmaceuticals USA, INC. | $17.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Loeber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.